Background: The viral RNA-dependent RNA polymerase (RdRp) enzymes of the Flaviviridae family are essential for viral replication and are logically important targets for development of antiviral therapeutic agents. Zika virus (ZIKV) is a rapidly re-emerging human pathogen for which no vaccine or antiviral agent is currently available. Methods: To facilitate development of ZIKV RdRp inhibitors, we have established an RdRp assay using purified recombinant ZIKV NS5 polymerase. Results: We have shown that both the hepatitis C virus (HCV) nucleoside inhibitor sofosbuvir triphosphate and a pyridoxine-derived non-nucleoside small-molecule inhibitor, DMB213, can act against ZIKV RdRp activity at IC 50 s of 7.3 and 5.2 μM, respectively, in RNA synthesis reactions catalysed by recombinant ZIKV NS5 polymerase. Cell-based assays confirmed the anti-ZIKV activity of sofosbuvir and DMB213 with 50% effective concentrations (EC 50 s) of 8.3 and 4.6 μM, respectively. Control studies showed that DMB213 did not inhibit recombinant HIV-1 reverse transcriptase and showed only very weak inhibition of HIV-1 integrase strand-transfer activity. The S604T substitution in motif B of the ZIKV RdRp, which corresponds to the S282T substitution in motif B of HCV RdRp, which confers resistance to nucleotide inhibitors, also conferred resistance to sofosbuvir triphosphate, but not to DMB213. Enzyme assays showed that DMB213 appears to be competitive with natural nucleoside triphosphate (NTP) substrates. Conclusions: Recombinant ZIKV RdRp assays can be useful tools for the screening of both nucleos(t)ide compounds and non-nucleotide metal ion-chelating agents that interfere with ZIKV replication.
Background: The viral RNA-dependent RNA polymerase (RdRp) enzymes of the Flaviviridae family are essential for viral replication and are logically important targets for development of antiviral therapeutic agents. Zika virus (ZIKV) is a rapidly re-emerging human pathogen for which no vaccine or antiviral agent is currently available. Methods: To facilitate development of ZIKV RdRp inhibitors, we have established an RdRp assay using purified recombinant ZIKV NS5 polymerase. Results: We have shown that both the hepatitis C virus (HCV) nucleoside inhibitor sofosbuvir triphosphate and a pyridoxine-derived non-nucleoside small-molecule inhibitor, DMB213, can act against ZIKV RdRp activity at IC 50 s of 7.3 and 5.2 μM, respectively, in RNA synthesis reactions catalysed by recombinant ZIKV NS5 polymerase. Cell-based assays confirmed the anti-ZIKV activity of sofosbuvir and DMB213 with 50% effective concentrations (EC 50 s) of 8.3 and 4.6 μM, respectively. Control studies showed that DMB213 did not inhibit recombinant HIV-1 reverse transcriptase and showed only very weak inhibition of HIV-1 integrase strand-transfer activity. The S604T substitution in motif B of the ZIKV RdRp, which corresponds to the S282T substitution in motif B of HCV RdRp, which confers resistance to nucleotide inhibitors, also conferred resistance to sofosbuvir triphosphate, but not to DMB213. Enzyme assays showed that DMB213 appears to be competitive with natural nucleoside triphosphate (NTP) substrates. Conclusions: Recombinant ZIKV RdRp assays can be useful tools for the screening of both nucleos(t)ide compounds and non-nucleotide metal ion-chelating agents that interfere with ZIKV replication.
Authors: Patrícia Brasil; Patricia Carvalho Sequeira; Andrea D'Avila Freitas; Heruza Einsfeld Zogbi; Guilherme Amaral Calvet; Rogerio Valls de Souza; André Machado Siqueira; Marcos Cesar Lima de Mendonca; Rita Maria Ribeiro Nogueira; Ana Maria Bispo de Filippis; Tom Solomon Journal: Lancet Date: 2016-04-02 Impact factor: 79.321
Authors: Hong-Tao Xu; Susan P Colby-Germinario; Said Hassounah; Peter K Quashie; Yingshan Han; Maureen Oliveira; Brent R Stranix; Mark A Wainberg Journal: Antimicrob Agents Chemother Date: 2015-11-16 Impact factor: 5.191
Authors: Hélène Malet; Marie-Pierre Egloff; Barbara Selisko; Rebecca E Butcher; Peter J Wright; Michael Roberts; Arnaud Gruez; Gerlind Sulzenbacher; Clemens Vonrhein; Gérard Bricogne; Jason M Mackenzie; Alexander A Khromykh; Andrew D Davidson; Bruno Canard Journal: J Biol Chem Date: 2007-02-07 Impact factor: 5.157
Authors: Shannan L Rossi; Robert B Tesh; Sasha R Azar; Antonio E Muruato; Kathryn A Hanley; Albert J Auguste; Rose M Langsjoen; Slobodan Paessler; Nikos Vasilakis; Scott C Weaver Journal: Am J Trop Med Hyg Date: 2016-03-28 Impact factor: 2.345
Authors: Ludek Eyer; Antoine Nougairède; Marie Uhlířová; Jean-Sélim Driouich; Darina Zouharová; James J Valdés; Jan Haviernik; Ernest A Gould; Erik De Clercq; Xavier de Lamballerie; Daniel Ruzek Journal: J Virol Date: 2019-07-30 Impact factor: 5.103
Authors: Melina Mottin; Lindsay K Caesar; David Brodsky; Nathalya C M R Mesquita; Ketllyn Zagato de Oliveira; Gabriela Dias Noske; Bruna K P Sousa; Paulo R P S Ramos; Hannah Jarmer; Bonnie Loh; Kimberley M Zorn; Daniel H Foil; Pedro M Torres; Rafael V C Guido; Glaucius Oliva; Frank Scholle; Sean Ekins; Nadja B Cech; Carolina H Andrade; Scott M Laster Journal: Bioorg Chem Date: 2022-01-31 Impact factor: 5.307
Authors: Juan-Carlos Saiz; Miguel A Martín-Acebes; Rubén Bueno-Marí; Oscar D Salomón; Luis C Villamil-Jiménez; Jorg Heukelbach; Carlos H Alencar; Paul K Armstrong; Tania M Ortiga-Carvalho; Rosalia Mendez-Otero; Paulo H Rosado-de-Castro; Pedro M Pimentel-Coelho Journal: Front Microbiol Date: 2017-08-22 Impact factor: 5.640